Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-09-04
2007-09-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
10185745
ABSTRACT:
The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
REFERENCES:
patent: 4704402 (1987-11-01), Abraham et al.
patent: 4723958 (1988-02-01), Pope et al.
patent: 4747825 (1988-05-01), Linkie et al.
patent: 4958592 (1990-09-01), Anthony et al.
patent: 4965251 (1990-10-01), Stamatoyannopoulos
patent: 5100647 (1992-03-01), Agus et al.
patent: 5403590 (1995-04-01), Forse
patent: 5674898 (1997-10-01), Cheng et al.
patent: 5750571 (1998-05-01), Cheng et al.
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5858365 (1999-01-01), Faller et al.
patent: 5939456 (1999-08-01), Perrine et al.
patent: WO92/04913 (1992-04-01), None
patent: WO93/18761 (1993-09-01), None
patent: WO94/04671 (1994-03-01), None
patent: WO95/11699 (1995-05-01), None
patent: WO96/27369 (1996-09-01), None
patent: WO97/04761 (1997-02-01), None
patent: WO98/04290 (1998-02-01), None
patent: WO98/40078 (1998-09-01), None
patent: WO98/56370 (1998-12-01), None
Rubenstein, et al.: “A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) In DELTAF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function” American Journal of Respiratory and Critical Care Medicine, (Feb. 1998), vol. 157, No. 2 pp. 484-490.
Walsh, et al.: “Combination of Drug and Gene Delivery by Gelatin Nanospheres for the Treatment of Cystic Fibrosis” Proceedings of the International Symposium on Controlled Release of Bioactive Materials, U.S., Deerfield, IL, controlled Release Soc., vol. SYMP, 24, Jun. 15, 1997, pp. 75-76.
Rubenstein et al.: “In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta.F508-CFTR” Journal of Clinical Investigation, U.S., New York, NY, vol. 10, No. 100, Nov. 15, 1997, pp. 2457-2465.
Konstan, Michael et al.: “Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis”, New England Journal of Medicine, (1995) vol. 332, No. 13, pp. 848-854.
Cheng, S.H. et al., Functional activation of the cystic fibrosis trafficking mutant ΔF508-CFTR by expression, Am. J. Physiol., 268:L615-24 (1995).
Faller Douglas V.
Perrine Susan P.
Stamatoyannopoulos George
LandOfFree
Compositions and methods for the treatment of cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of cystic fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3789509